nAMD treatment options may offer positive outcomes to patients by reducing fluid fluctuations associated with poorer outcomes. To counter this, health care providers often tailor individual treatment ...

Choroidal dysfunction plays a crucial role in retinal diseases, highlighting its potential as a therapeutic target and the need for innovative treatments. Increasingly, the choroid is being recognized ...

Ophthalmology advances with AI diagnostics and pediatric trauma insights, merging technology and compassion to enhance patient care and outcomes. From surgical innovations to artificial intelligence ...

Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of Ophthalmology Times for more than 20 ...

Prof Dr Rajvardhan Azad explains how unified guidelines, AI-driven tools, and cross-disciplinary collaboration could transform outcomes for premature infants. As retinopathy of prematurity (ROP) ...

Dr. J. Peter Campbell discusses the technologies shaping retinopathy of prematurity detection, clinical integration, and global implementation. As artificial intelligence (AI) continues to reshape the ...

Modern Retina November and December 2025 | Modern Retina Digital Edition | Journal | Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in ...

The company noted that this approval marks Celltrion's first Health Canada-approved biologic product in ophthalmology. The Health Canada approval was based on a “totality of evidence including ...

According to the company, this is the first and only single-use kit on the market that includes the diagnostic lens.Corza Medical has announced the commercial launch of the SensorTek ROP Kit, a single ...

The upcoming The FLORetina International Congress on OCT Angiography, En Face OCT, and Advances in OCT (FLORetina-ICOOR) in Florence, Italy, is hosting 57 exhibitors who will showcase their latest ...

The Data Safety Monitoring Committee (DSMC) recently completed its second scheduled review of EyePoint Pharmaceuticals’ ongoing phase 3 trial evaluating DURAVYU for the treatment of wet AMD (wAMD), ...

For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice. In this installment, ...